Direxion S&P Biotech Bull 3X

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Apellis Pharma released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 268.3 M (forecast USD 203.29 M), actual EPS USD 0.1461 (forecast USD -0.3526)

Revolution Medicines released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 0 (forecast USD 2.425 M), actual EPS USD -2.2908 (forecast USD -1.8344)

Revolution Medicines Submits NDA for Daraxonrasib

Revolution Medicines reports Q1 operating loss of $445.222 million

TG Therap released FY2026 Q1 earnings on May 6 During-Market (EST), actual revenue USD 204.92 M (forecast USD 201.21 M), actual EPS USD 0.1199 (forecast USD 0.2719)

Revolution Medicines Exec Exercised Stock Options and Sold Shares

Revolution Medicines to release FY2026 Q1 earnings on May 6 After-Market EST, forecast revenue USD 2.425 M, EPS USD -1.8392

TG Therap to Release FY2026 Q1 Earnings on May 6 During Market Hours (EST), Forecast Revenue USD 200.92 M, EPS USD 0.2719

Revolution Medicines Sues Erasca for Patent Infringement, Stock Rises

Mizuho Maintains Buy Rating on Revolution Medicines, Targeting $185

Revolution Medicines Releases RM-055 Preclinical Data

Revolution Medicines Publishes Clinical Data for Daraxonrasib in Treating Pancreatic Cancer

Revolution Medicines issues $250 million convertible senior notes

Revolution Medicines' daraxonrasib shows positive results in pancreatic cancer phase III trial

Biogen plans to acquire Apellis

Tema Etfs LLC Reduced Holdings in Revolution Medicines, Inc.

Biogen to acquire Apellis Pharmaceuticals for $41 per share

Amesite

InMed Pharmaceuticals

Meiwu Tech

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

MetaVia

Co-Diagnostics

Phoenix Asia

NextNRG

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Pinned News

置顶新闻

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

HOTH

LABU

Hoth Therapeutics Inc. plans to rebrand as Rocket One Inc. to focus on AI semiconductor technologies and ultra-low-power AI computing. The board unanimously approved this strategic shift, which includes securing exclusive rights to technologies from Virginia Commonwealth University. The company will maintain its biotechnology operations while addressing AI infrastructure challenges. Hoth's shares fell 9.69% to $0.55 in premarket trading, reflecting a 20.9% decline over the past month.

benzinga_article

Hoth Therapeutics

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

S&P 500

UCBJY

SBIO

ARKG

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

UCB S.A.

United Community Banks

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares US Pharma

VG Health

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

AMIX

A revolutionary technology has been developed that allows for minimally invasive transvascular access to nerve targets and tissues. This innovative method enables access through and beyond the lumen wall, providing a less invasive approach for procedures. This breakthrough is set to significantly improve treatment options for patients, with a success rate of over 90% in initial clinical trials. This technology is expected to benefit a wide range of medical fields and has the potential to transform minimally invasive procedures globally.

Unusual Whales

Autonomix Medical

iShares US Medical Devices

SPDR S&P Health Equip

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Nexalin has completed the acquisition of the PONM digital health platform from GreenLight Ventures for $1.3 million, paid in Nexalin stock. The deal includes an exclusive license for AI-enabled software features and supports a planned FDA trial for HALO Clarity. GreenLight will also become an equity holder and provide ongoing support.

PUBT

Nexalin Tech

NEXALIN TECHNOLOGY INC C/WTS 22/09/25(TO PUR COM)

Nexalin closes acquisition of PONM digital health platform for USD 1.3 million

RNXT

RenovoRx (RNXT) reported a record Q1 2026 revenue of $563,000, a 136% increase from Q4 2025. The company has expanded its commercial cancer centers to 16 and aims for 36 by year-end. Management reiterated a 2026 revenue target of $3-4 million, supported by a strong pipeline and cash position of $12.4 million. The TIGER-PACT Phase III trial is nearing completion, with 93% of patient enrollment achieved. Operating expenses are expected to remain stable, facilitating further revenue growth.

Motley Fool

RenovoRx

RenovoRx (RNXT) Q1 2026 Earnings Transcript

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

Market Beat

West Pharmaceutical

Arcadian Asset

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

BAYN

BAYRY

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

TLSA

Tiziana Life Sciences reported positive data from its expanded-access program for intranasal foralumab in 14 patients with non-active secondary progressive multiple sclerosis. The treatment was well tolerated, with no new safety concerns, and patients showed trends toward stabilizing disability and improvements in fatigue. The company supports further development but notes the small dataset limits conclusions.

Tiziana Life Sciences

Tiziana reports positive expanded-access data for intranasal foralumab in non-active SPMS

LTRN

Lantern Pharma has successfully cleared key protocol changes for its Phase 2 HARMONIC trial of LP-300, focusing on a specific EGFR mutation in never-smokers with advanced non-small cell lung cancer. The study will shift to a single-arm design to expedite enrollment and improve data clarity. Treatment duration will be extended, with further clinical updates expected in the second half of 2026.

Lantern Pharma

Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus

NTHI

Maxim Group, Alliance Global Partners, and BTIG Research have initiated coverage of NeOnc Technologies, all providing favorable ratings and price targets. This increased analyst attention comes ahead of the anticipated interim Phase 2a data for the lead candidate NEO100.

Neonc Tech

Maxim Group, Alliance Global, BTIG initiate coverage of NeOnc Technologies

Resona Asset Management Co. Ltd. reduced its stake in Danaher Corporation (NYSE:DHR) by 12.7% in Q4, now holding 448,050 shares valued at approximately $102.77 million. Other institutional investors have also adjusted their positions. Analysts have lowered price targets for Danaher, with a consensus rating of 'Moderate Buy' and a price target of $238.65. Danaher reported a quarterly EPS of $2.06, exceeding estimates, and announced a quarterly dividend of $0.40.

Danaher

Goldman Sachs

Wells Fargo

Johnson Controls

GS Hldg R

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR

Direxion S&P Biotech Bull 3X(LABU.US)